<DOC>
	<DOC>NCT01679483</DOC>
	<brief_summary>To compare the incidence of lymphocele and lymphatic ascites between patient who use versus who do not use FloSeal during lymph node dissection</brief_summary>
	<brief_title>Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Lymphocele</mesh_term>
	<criteria>Histologically confirmed primary cancer of the uterine cervix, uterine corpus, ovary, and fallopian tube FIGO stage Cervical cancer: FIOG stage IA2IIA2 Uterine cancer: FIGO stage IIII Ovarian and fallopian tubal cancer: FIGO stage IIIIB Patients who undergoing surgery including pelvic and/or paraaortic lymph node dissection Patients with adequate bone marrow, renal and hepatic function: WBC &gt; 3,000 cells/mcl Platelets &gt;100,000/mcl Creatinine &lt;2.0 mg/dL Bilirubin &lt;1.5 x normal and SGOT or SGPT &lt;3 x normal American Society of Anesthesiology Physical Status 01 Performance status of ECOG 02 Patient must be suitable candidates for surgery Patients who have signed an approved Informed Consent Patients with a history of pelvic or abdominal radiotherapy; Patients who are pregnant Patients with contraindications to surgery; Patients who are unfit for Surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); Patient's compliance and geographic proximity that do not allow adequate followup. Patients who undergo only lymph node sampling</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>